Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)

Abstract excerpt

INTRODUCTION: Cell cycle deregulation is a common characteristic of cancer cells. Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of molecular mechanisms. Based on these observations, small molecule CDK inhibitors are being developed as potential cancer therapeutics. Some of these compounds have entered Phase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Cancer Mechanisms and Therapy
• Share to Cancer-related Molecular Pathways